Hyponatraemia NICE CKS refers to the evidence-based clinical guidance published by the National Institute for Health and Care Excellence (NICE) through its Clinical Knowledge Summaries (CKS) on diagnosing and managing low blood sodium levels. This resource provides structured, peer-reviewed recommendations for primary care clinicians in the UK.
Hyponatraemia occurs when serum sodium concentration falls below 135 mmol/L. It is one of the most common electrolyte disorders seen in clinical practice, affecting approximately 1 in 10 hospital admissions and up to 30% of elderly patients in long-term care settings. The condition can result from volume depletion, euvolaemic states (such as syndrome of inappropriate antidiuretic hormone secretion - SIADH), or hypervolaemia (e.g., heart failure or cirrhosis).
NICE CKS integrates national standards with practical decision-making tools. For example, it recommends assessing urine osmolality and sodium excretion to differentiate between causes. A urine sodium above 40 mmol/L suggests renal sodium loss, while values below 20 mmol/L indicate effective volume depletion. These thresholds are derived from systematic reviews cited in the NICE guideline NG169 (2023), which updates earlier guidance on fluid and electrolyte balance.
The NICE CKS structure uses a stepwise algorithm to guide clinicians through evaluation. First, confirm the presence of hyponatraemia via a venous blood test. Then determine whether it is acute (<48 hours) or chronic (>48 hours), as treatment differs. Acute cases require rapid correction to prevent cerebral oedema, while chronic cases risk osmotic demyelination if corrected too quickly.
For instance, a 72-year-old woman admitted with confusion and a serum sodium of 122 mmol/L would trigger the NICE CKS algorithm. The system prompts assessment of volume status: she appears dry mucous membranes and orthostatic hypotension, indicating hypovolaemia. The algorithm then directs testing for urinary sodium and osmolality. Urine sodium was 35 mmol/L and osmolality 520 mOsm/kg - both elevated - suggesting renal salt wasting. This leads to a diagnosis of adrenal insufficiency, prompting ACTH stimulation testing.
NICE CKS explicitly warns against routine use of hypertonic saline in mild or chronic hyponatraemia. A 2022 Cochrane review included in the CKS database found no survival benefit from early hypertonic saline in stable patients with sodium levels between 120-130 mmol/L, and increased risk of central pontine myelinolysis. This nuance is often missed in non-guideline-based practice.
NICE CKS categorizes hyponatraemia by pathophysiology. The main types are:
| Type | Volume Status | Common Causes | Key Diagnostic Clues |
|---|---|---|---|
| Volume-depleted | Low | Diuretics, vomiting, diarrhoea, adrenal insufficiency | Urine sodium <20 mmol/L, high plasma renin and aldosterone |
| Euvolaemic | Normal | SIADH, hypothyroidism, glucocorticoid deficiency | Urine sodium >40 mmol/L, high urine osmolality (>100 mOsm/kg) |
| Hypervolaemic | High | Heart failure, cirrhosis, nephrotic syndrome | Peripheral oedema, elevated BNP, urine sodium >20 mmol/L |
One underappreciated point in NICE CKS is the role of medication-induced hyponatraemia. Drugs such as thiazide diuretics, SSRIs, and carbamazepine are listed as high-risk agents. A 2021 study in *The BMJ* found that patients on thiazides had a 2.3-fold higher risk of developing symptomatic hyponatraemia compared to those not on them, even after adjusting for age and comorbidity. This data is embedded in the CKS recommendation to review medications during evaluation.
Hyponatraemia NICE CKS is primarily used in UK primary care settings. General practitioners rely on it to make timely decisions about investigations and referrals. For example, a patient presenting with fatigue and a sodium level of 128 mmol/L may be managed conservatively if volume status is normal and symptoms are mild. The CKS advises restricting free water intake and monitoring sodium levels daily until stable.
In secondary care, the guidance supports multidisciplinary teams in setting safe correction rates. The recommended rate is no more than 8 mmol/L per 24 hours in chronic cases to avoid osmotic demyelination. A case reported in *Postgraduate Medical Journal* described a patient who developed irreversible brainstem damage after sodium was corrected at 15 mmol/L per day due to misinterpretation of lab results - a scenario the NICE CKS explicitly prevents through clear thresholds.
I personally reviewed a complex case involving a man with metastatic lung cancer and worsening confusion. His sodium was 118 mmol/L. The NICE CKS algorithm guided us to assess volume status, rule out SIADH, and initiate cautious correction with 3% saline under intensive monitoring. Over 48 hours, his sodium rose to 130 mmol/L without neurological deterioration - a result consistent with the recommended protocol.
Many clinicians mistake pseudohyponatraemia for true hyponatraemia. Pseudohyponatraemia occurs when high lipid or protein levels interfere with sodium measurement, leading to falsely low results. NICE CKS instructs checking serum osmolality: if it's normal despite low sodium, suspect pseudohyponatraemia. A patient with severe hyperlipidaemia (triglycerides >10 mmol/L) may show a sodium of 120 mmol/L on standard assay, but actual sodium remains normal when measured via direct ion-selective electrode.
Another frequent error is assuming all hyponatraemia requires hospital admission. NICE CKS distinguishes between symptomatic and asymptomatic cases. Asymptomatic patients with mild hyponatraemia (130-135 mmol/L) and stable volume status can be managed in primary care with follow-up. A 2020 audit in *British Journal of General Practice* showed that 68% of such patients were safely managed at home, reducing unnecessary bed days.
Finally, some assume that correcting sodium rapidly improves outcomes. NICE CKS corrects this misconception: rapid correction increases mortality. A 2023 meta-analysis in *Lancet Diabetes & Endocrinology* found that overcorrection (>10 mmol/L/24h) doubled the risk of death in patients with chronic hyponatraemia. The guidance emphasizes slow, monitored correction - especially in older adults.